The role that artificial intelligence (AI) and other technology can play in care delivery is growing, said Coral Omene, MD, ...

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia ...

Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).

Epcoritamab demonstrated a median CR of 36 months and a median progression-free survival of 37 months in LBCL patients.

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Xavier Leleu, MD, PhD, is the head of the Department of Haematology and the Myeloma Clinic at Hôpital La Mileterie, in Poitiers, France.